Literature DB >> 3293772

Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review.

J L Grem1, S A King, P J O'Dwyer, B Leyland-Jones.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3293772

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  20 in total

1.  Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside (MMPR), and leucovorin in patients with advanced cancer.

Authors:  A Hageboutros; G R Hudes; F Greene; F P LaCreta; J Brennan; P J O'Dwyer
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

2.  The nucleotide synthesis enzyme CAD inhibits NOD2 antibacterial function in human intestinal epithelial cells.

Authors:  Amy L Richmond; Amrita Kabi; Craig R Homer; Noemí Marina-García; Kourtney P Nickerson; Alexey I Nesvizhskii; Arun Sreekumar; Arul M Chinnaiyan; Gabriel Nuñez; Christine McDonald
Journal:  Gastroenterology       Date:  2012-02-28       Impact factor: 22.682

3.  Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.

Authors:  A Hageboutros; A Rogatko; E M Newman; C McAleer; J Brennan; F P LaCreta; G R Hudes; R F Ozols; P J O'Dwyer
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

4.  A novel mechanism for resistance to the antimetabolite N-phosphonoacetyl-L-aspartate by Helicobacter pylori.

Authors:  B P Burns; G L Mendz; S L Hazell
Journal:  J Bacteriol       Date:  1998-11       Impact factor: 3.490

5.  A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study.

Authors:  Robert P Whitehead; Jacqueline K Benedetti; James L Abbruzzese; Bach Ardalan; Stephen Williamson; Ellen R Gaynor; Stanley P Balcerzak; John S Macdonald
Journal:  Invest New Drugs       Date:  2004-11       Impact factor: 3.850

6.  Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937.

Authors:  D H Horber; H Schott; R A Schwendener
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  Modulation of human ovarian tumor cell sensitivity to N-(phosphonacetyl)-L-aspartate (PALA) by liposome drug carriers.

Authors:  A Sharma; N L Straubinger; R M Straubinger
Journal:  Pharm Res       Date:  1993-10       Impact factor: 4.200

8.  Biochemical modulation of 5-fluorouracil with or without leucovorin by a low dose of brequinar in MGH-U1 cells.

Authors:  T L Chen; C Erlichman
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

9.  Submicromolar phosphinic inhibitors of Escherichia coli aspartate transcarbamoylase.

Authors:  Laëtitia Coudray; Evan R Kantrowitz; Jean-Luc Montchamp
Journal:  Bioorg Med Chem Lett       Date:  2008-12-06       Impact factor: 2.823

10.  Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside.

Authors:  A Hageboutros; G R Hudes; J Brennan; F Green; J Hoffman; F P LaCreta; J Colofiore; D S Martin; R F Ozols; P J O'Dwyer
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.